SkinnyRx's website misbranded compounded semaglutide and tirzepatide by wrongly suggesting it makes the drugs and that they are FDA-approved.
What happened
FDA reviewed the website https://skinnyrx.com in December 2025 and saw that it offers compounded semaglutide and tirzepatide drug products. The pictured product labels carry the name "SkinnyRx," which FDA says wrongly suggests SkinnyRx is the compounder, and the site makes claims comparing the products to FDA-approved name-brand GLP-1 medicines. FDA says these statements are false or misleading, which makes the products misbranded.
What FDA found
The website's product labels show "SkinnyRx" as if SkinnyRx made the drugs, but it does not, so the labeling is false or misleading.
FDCA § 502(a) [21 U.S.C. § 352(a)]; 21 CFR § 201.1(h)(2)The website says the products are "from the same family as GLP-1 treatments like Mounjaro and Zepbound" and have "the same active ingredient as name-brand GLP-1 medications," which suggests they are FDA-approved when they are not.
FDCA §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]Advertising for a compounded drug that is false or misleading in any way makes the drug misbranded.
FDCA § 502(bb) [21 U.S.C. § 352(bb)]Sending these misbranded drugs, or delivering them for shipment, in interstate commerce is a prohibited act.
FDCA § 301(a) [21 U.S.C. § 331(a)]Receiving misbranded drugs in interstate commerce, or delivering them, is also a prohibited act.
FDCA § 301(c) [21 U.S.C. § 331(c)]
What FDA wants
Within 15 working days, SkinnyRx must send the Office of Compounding Quality and Compliance a written response describing the steps it has taken, naming the entities that actually make the products, providing sample labeling, and fixing or removing the misleading claims. If it cannot finish in that time, it must explain why and give a date.
Who should pay attention
- telehealth companies that market compounded GLP-1 drugs
- marketers and resellers that put their own name on product made by someone else
- compounding pharmacies whose products are sold under another company's brand
This is a summary. Read the original letter on fda.gov.